Why the study?
Does intravenous nifedipine infusion provide safe and stable pharmacokinetics in patients with acute myocardial infarction?
Does intravenous nifedipine infusion provide safe and stable pharmacokinetics in patients with acute myocardial infarction?
Intravenous nifedipine infusion in acute myocardial infarction achieves steady plasma concentrations without increasing myocardial oxygen requirements, but its use via peripheral veins is limited by a high rate of thrombophlebitis.
Answers are grounded in this paper and cite their sources.
Supports stable IV nifedipine pharmacokinetics in AMI without raising myocardial O2 demand; leaves open clinical role pending controlled trials.
Studies of nifedipine have not shown that it reduces myocardial infarct size in humans. These studies did not consider the pharmacokinetics and dynamics of nifedipine. Oral doses of nifedipine cause high plasma concentrations and possibly harmful hemodynamic changes. Intravenous nifedipine infusion can rapidly achieve and maintain a steady concentration without repeated hemodynamic upsets. We studied 24-h intravenous nifedipine infusion in 12 patients with acute myocardial infarct, starting within 6 (mean 4.0 +/- 0.7) h of onset of pain, to determine its safety, pharmacokinetics, and dynamics. An intravenous nifedipine bolus of 15 micrograms/kg was followed by an infusion of 0.9 mg/h for 24 h. After the bolus, pulse rate rose 12.5 +/- 8.0 p less than 0.01) and blood pressure fell (systolic by 20 +/- 34, p less than 0.05, and diastolic by 7.5 +/- 15.6, p less than 0.05). There were similar but lesser changes during the infusion. Myocardial oxygen requirements, as measured by the rate-pressure product, did not increase. The mean nifedipine concentration at steady state was 17.2 +/- 4.2 ng/ml and mean elimination T 1/2 3.57 +/- 2.70 h. Nifedipine was discontinued in 3 patients because of hypotension (SBP less than 90), rapid atrial fibrillation, and complete heart block in one patient each. Seven patients developed thrombophlebitis. Large studies of this preparation examining infarct size limitation and mortality are feasible, although in view of the problems of thrombophlebitis in peripheral veins, shorter infusion times or infusion via central lines would be more acceptable.
No takes yet. Share an insight, caveat, or question.
Heagerty et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: